Segment Information

9 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Segment Information

13. Segment Information

Segment revenue, operating income (loss), and depreciation and amortization were as follows:

	Three Months Ended June 30,						Nine Months Ended June 30,
(In thousands)	2023			2022			2023			2022
Revenue:
Medical Device	$	46,014		$	17,528		$	84,739		$	52,889
In Vitro Diagnostics		6,469			7,326			19,875			21,074
Total revenue	$	52,483		$	24,854		$	104,614		$	73,963
Operating income (loss):
Medical Device	$	21,777		$	(7,308	)	$	7,483		$	(16,712	)
In Vitro Diagnostics		2,866			3,387			9,450			10,262
Total segment operating income (loss)		24,643			(3,921	)		16,933			(6,450	)
Corporate		(3,231	)		(3,222	)		(9,333	)		(9,034	)
Total operating income (loss)	$	21,412		$	(7,143	)	$	7,600		$	(15,484	)
Depreciation and amortization:
Medical Device	$	1,997		$	2,020		$	5,883		$	6,347
In Vitro Diagnostics		78			88			230			260
Corporate		76			98			252			295
Total depreciation and amortization	$	2,151		$	2,206		$	6,365		$	6,902

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.